Li Lu, Dou Lixia, Leung Ping Chung, Chung Tony Kwok Hung, Wang Chi Chiu
Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Terrorities, Hong Kong.
Cochrane Database Syst Rev. 2016 Jan 14;2016(1):CD010568. doi: 10.1002/14651858.CD010568.pub2.
BACKGROUND: Recurrent miscarriage affects 1% to 3% of women of reproductive age and mostly occurs before the 10th week of gestation (and around the same gestational week in subsequent miscarriages). Although most pregnant women may not recognise a miscarriage until uterine bleeding and cramping occur, a repeat miscarriage after one or more pregnancy loss and the chance of having a successful pregnancy varies. To date, there is no universally accepted treatment for unexplained recurrent miscarriage. Chinese herbal medicines have been widely used in Asian societies for millennia and have become a popular alternative to Western medicines in recent years. Many clinical studies have reported that Chinese herbal medicines can improve pregnancy outcomes for pregnant women who had previously suffered recurrent miscarriage. This systematic review evaluated the efficacy of Chinese herbal medicines for recurrent miscarriage. OBJECTIVES: To assess the effectiveness and safety of Chinese herbal medicines for the treatment of unexplained recurrent miscarriage. SEARCH METHODS: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (01 June 2015), Embase (1980 to 01 June 2015); Cumulative Index to Nursing and Allied Health Literature (CINAHL) (1982 to 01 June 2015); Chinese Biomedical Database (CBM) (1978 to 01 June 2015); China Journal Net (CJN) (1915 to 01 June 2015); China Journals Full-text Database (1915 to 01 June 2015); and WanFang Database (Chinese Ministry of Science & Technology) (1980 to 01 June 2015). We also searched reference lists of relevant trials and reviews. We identified and contacted organisations, individual experts working in the field, and medicinal herb manufacturers. SELECTION CRITERIA: Randomised or quasi-randomised controlled trials, including cluster-randomised trials, with or without full text, comparing Chinese herbal medicines (alone or combined with other intervention or other pharmaceuticals) with placebo, no treatment, other intervention (including bed rest and psychological support), or other pharmaceuticals as treatments for unexplained recurrent miscarriage. Cross-over studies were not eligible for inclusion in this review. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed all the studies for inclusion in the review, assessed risk of bias and extracted the data. Data were checked for accuracy. MAIN RESULTS: We included nine randomised clinical trials (involving 861 women). The trials compared Chinese herbal medicines (various formulations) either alone (one trial), or in combination with other pharmaceuticals (seven trials) versus other pharmaceuticals alone. One study compared Chinese herbal medicines and other pharmaceuticals versus psychotherapy. We did not identify any trials comparing Chinese herbal medicines with placebo or no treatment, including bed rest.Various Chinese herbal medicines were used in the different trials (and some of the classical the formulations were modified in the trials). The Western pharmaceutical medicines included tocolytic drugs such as salbutamol and magnesium sulphate; hormonal supplementation with human chorionic gonadotrophin (HCG), progesterone or dydrogesterone; and supportive supplements such as vitamin E, vitamin K and folic acid.Overall, the methodological quality of the included studies was poor with unclear risk of bias for nearly all the 'Risk of bias' domains assessed.Chinese herbal medicines alone versus other pharmaceuticals alone - the live birth rate was no different between the two groups (risk ratio (RR) 1.05; 95% confidence interval (CI) 0.67 to 1.65; one trial, 80 women). No data were available for the outcome of pregnancy rate (continuation of pregnancy after 20 weeks of gestation).In contrast, the continuing pregnancy rate (RR 1.27 95% CI 1.10 to 1.48, two trials, 189 women) and live birth rate (average RR 1.55; 95% CI 1.14 to 2.10; six trials, 601 women, Tau² = 0.10; I² = 73%) were higher among the group of women who received a combination of Chinese herbal medicines and other pharmaceuticals when compared with women who received other pharmaceuticals alone.For Chinese herbal medicines and psychotherapy versus psychotherapy alone (one study) - there was a higher live birth rate (RR 1.32; 95% CI 1.07 to 1.64; one trial, 90 women) in the group of women who received a combination of Chinese herbal medicines and psychotherapy compared to those women who received psychotherapy alone. No data were available on the continuing pregnancy rate for this comparison.Other primary outcomes (maternal adverse effect and toxicity rate and the perinatal adverse effect and toxicity rate) were not reported in most of the included studies. Two trials (341 women) reported that no maternal adverse effects were found (one trial compared (combined) medicines with other pharmaceuticals, and one trial compared combined Chinese herbal medicine alone versus other pharmaceuticals). One trial (Chinese herbal medicine alone versus other pharmaceuticals alone) reported that there were no abnormal fetuses (ultrasound) or after delivery.There were no data reported for any of this review's secondary outcomes. AUTHORS' CONCLUSIONS: We found limited evidence (from nine studies with small sample sizes and unclear risk of bias) to assess the effectiveness of Chinese herbal medicines for treating unexplained recurrent miscarriage; no data were available to assess the safety of the intervention for the mother or her baby. There were no data relating to any of this review's secondary outcomes. From the limited data we found, a combination of Chinese herbal medicines and other pharmaceuticals (mainly Western medicines) may be more effective than Western medicines alone in terms of the rate of continuing pregnancy and the rate of live births. However, the methodological quality of the included studies was generally poor.A comparison of Chinese herbal medicines alone versus placebo or no treatment (including bed rest) was not possible as no relevant trials were identified.More high-quality studies are needed to further evaluate the effectiveness and safety of Chinese herbal medicines for unexplained recurrent miscarriage. In addition to assessing the effect of Chinese herbal medicines on pregnancy rate and the rate of live births, future studies should also consider safety issues (adverse effects and toxicity for the mother and her baby) as well as the secondary outcomes listed in this review. This review would provide more valuable information if the included studies could overcome the problems in their designs, such as lacking of qualified placebo-controlled trials, applying adequate randomisation methods and avoiding potential bias.
背景:复发性流产影响1%至3%的育龄妇女,大多发生在妊娠第10周之前(后续流产发生在大致相同孕周)。虽然大多数孕妇在子宫出血和腹痛发生之前可能并未意识到流产,但经历一次或多次妊娠丢失后的复发性流产以及成功妊娠的几率因人而异。迄今为止,对于不明原因的复发性流产尚无普遍接受的治疗方法。几千年来,中草药在亚洲社会广泛使用,近年来已成为西药的一种流行替代物。许多临床研究报告称,中草药可改善既往有复发性流产史孕妇的妊娠结局。本系统评价评估了中草药治疗复发性流产的疗效。 目的:评估中草药治疗不明原因复发性流产的有效性和安全性。 检索方法:我们检索了Cochrane妊娠与分娩组试验注册库(2015年6月1日)、Embase(1980年至2015年6月1日);护理学与健康相关学科累积索引数据库(CINAHL)(1982年至2015年6月1日);中国生物医学文献数据库(CBM)(1978年至2015年6月1日);中国期刊网(CJN)(1915年至2015年6月1日);中国期刊全文数据库(1915年至2015年6月1日);以及万方数据库(中国科学技术部)(1980年至2015年6月1日)。我们还检索了相关试验和综述的参考文献列表。我们识别并联系了该领域的组织、专家个人以及草药生产商。 选择标准:随机或半随机对照试验,包括整群随机试验,无论是否有全文,比较中草药(单独使用或与其他干预措施或其他药物联合使用)与安慰剂、不治疗、其他干预措施(包括卧床休息和心理支持)或其他药物作为不明原因复发性流产的治疗方法。交叉研究不符合纳入本综述的条件。 数据收集与分析:两位综述作者独立评估所有纳入综述的研究,评估偏倚风险并提取数据。对数据进行准确性检查。 主要结果:我们纳入了9项随机临床试验(涉及861名女性)。这些试验比较了单独使用中草药(各种配方)(1项试验)或与其他药物联合使用(7项试验)与单独使用其他药物。1项研究比较了中草药和其他药物与心理治疗。我们未识别出任何比较中草药与安慰剂或不治疗(包括卧床休息)的试验。不同试验中使用了各种中草药(且部分经典配方在试验中有所修改)。西药包括宫缩抑制剂如沙丁胺醇和硫酸镁;激素补充剂如人绒毛膜促性腺激素(HCG)、黄体酮或地屈孕酮;以及支持性补充剂如维生素E、维生素K和叶酸。总体而言,纳入研究的方法学质量较差,几乎所有评估的“偏倚风险”领域的偏倚风险均不明确。 单独使用中草药与单独使用其他药物相比——两组的活产率无差异(风险比(RR)1.05;95%置信区间(CI)0.67至1.65;1项试验,80名女性)。无妊娠率(妊娠20周后继续妊娠)结局的数据。 相比之下,与单独接受其他药物治疗的女性相比,接受中草药与其他药物联合治疗的女性组的继续妊娠率(RR 1.27,95%CI 1.10至1.48,2项试验,189名女性)和活产率(平均RR 1.55;95%CI 1.14至2.10;6项试验,601名女性,Tau² = 0.10;I² = 73%)更高。 对于中草药与心理治疗联合与单独心理治疗(1项研究)——接受中草药与心理治疗联合治疗的女性组的活产率(RR 1.32;95%CI 1.07至1.64;1项试验,90名女性)高于单独接受心理治疗的女性。此比较无继续妊娠率的数据。 大多数纳入研究未报告其他主要结局(母体不良反应和毒性率以及围产期不良反应和毒性率)。2项试验(341名女性)报告未发现母体不良反应(1项试验比较(联合)药物与其他药物,1项试验比较单独联合中草药与其他药物)。1项试验(单独使用中草药与单独使用其他药物)报告未发现异常胎儿(超声检查)或分娩后异常。本综述的任何次要结局均无报告数据。 作者结论:我们发现有限的证据(来自9项样本量小且偏倚风险不明确的研究)来评估中草药治疗不明原因复发性流产的有效性;无数据可评估该干预措施对母亲或其婴儿的安全性。本综述任何次要结局均无相关数据。根据我们发现的有限数据,中草药与其他药物(主要是西药)联合使用在继续妊娠率和活产率方面可能比单独使用西药更有效。然而,纳入研究的方法学质量总体较差。 由于未识别出相关试验,无法比较单独使用中草药与安慰剂或不治疗(包括卧床休息)。需要更多高质量研究来进一步评估中草药治疗不明原因复发性流产的有效性和安全性。除了评估中草药对妊娠率和活产率的影响外,未来研究还应考虑安全性问题(对母亲及其婴儿的不良反应和毒性)以及本综述列出的次要结局。如果纳入研究能够克服其设计中的问题,如缺乏合格的安慰剂对照试验、应用适当的随机方法并避免潜在偏倚,本综述将提供更有价值的信息。
Cochrane Database Syst Rev. 2016-1-14
Cochrane Database Syst Rev. 2016-7-25
Cochrane Database Syst Rev. 2021-4-19
Cochrane Database Syst Rev. 2025-6-11
Cochrane Database Syst Rev. 2021-4-19
Cochrane Database Syst Rev. 2020-1-9
Cochrane Database Syst Rev. 2012-5-16
Cochrane Database Syst Rev. 2017-9-22
Cochrane Database Syst Rev. 2017-12-22
Cochrane Database Syst Rev. 2016-1-14
Front Endocrinol (Lausanne). 2024
Front Pharmacol. 2023-2-14
Cochrane Database Syst Rev. 2018-11-14
Clin Endocrinol (Oxf). 2012-10
Reprod Biomed Online. 2012-4-3
Cochrane Database Syst Rev. 2012-5-16
Stress. 2001-9
J Reprod Immunol. 2011-12-21